News

Filter

Taiho Pharma drops orantinib Ph III trial

Taiho Pharma drops orantinib Ph III trial

04-08-2014

Japanese drugmaker Taiho Pharmaceutical says it is terminating a Phase III clinical trial (ORIENTAL trial)…

Hepatocellular carcinomaHepatologyJapanOncologyorantinibPharmaceuticalResearchS-1TACETaiho PharmaceuticalTSU-68

Taiho Pharma and Sumitomo Dainippon both invest in Remiges BioPharma Fund

25-07-2014

Japanese oncology-focussed drugmaker Taiho Pharmaceutical has said that it will be investing $30 million…

BiotechnologyDainippon Sumitomo PharmaFinancialJapanOncologyRemiges BioPharma FundTaiho Pharmaceutical

Taiho Oncology’s TAS-102 shows good results in colorectal cancer

Taiho Oncology’s TAS-102 shows good results in colorectal cancer

12-05-2014

Japanese firm Taiho Oncology, a subsidiary of Otsuka, has released positive results from its global Phase…

Health Medical PharmaHealth Medical PharmaJapanOncologyPharmaceuticalRefractory metastatic colorectal cancerResearchTaiho OncologyTaiho PharmaceuticalTAS-102United States

Japanese approval for Forxiga and Lonsurf

24-03-2014

Anglo-Swedish drug major AstraZeneca says that Japanese Ministry of Health, Labor and Welfare approved…

Asia-PacificAstraZenecaDiabetesForxigaJapanLonsurfOncologyOno PharmaceuticalOtsukaPharmaceuticalRegulationTaiho Pharmaceutical

Taiho Pharma files for approval of cancer drug TAS-102 in Japan

27-02-2013

Japanese drugmaker Taiho Pharmaceutical, a subsidiary of Otsuka (TYO: 4768) says that it submitted an…

Asia-PacificOncologyOtsukaPharmaceuticalRegulationTaiho PharmaceuticalTAS-102

Taiho to market Merck & Co’s CTLC drug vorinostat in Japan, where MSD is expelled from JPMA

17-06-2011

US drugs giant Merck & Co’s (NYSE: MRK) Japanese subsidiary has entered into an agreement with local…

Asia-PacificLicensingMarkets & MarketingMerck & CoOncologyOtsukaPharmaceuticalTaiho PharmaceuticalvorinostatZolinza

Helsinn and Taiho Pharma to extend relationship with CINV drug accord

14-04-2011

Privately-held Swiss company Helsinn Group and Taiho Pharmaceutical, a subsidiary of Otsuka (4768: JP)…

Asia-PacificHelsinnLicensingnetupitantOncologyPalonosetron hydrochloridePharmaceuticalTaiho Pharmaceutical

Otsuka gastric cancer drug Teysuno gets EU approval

16-03-2011

Japanese drugmaker Otsuka (4768: JP) says that its subsidiary Taiho Pharmaceutical has received approval…

EuropeOncologyOtsukaPharmaceuticalRegulationTaiho PharmaceuticalTeysuno

COMPANY SPOTLIGHT

Menarini

Back to top